Aprea Therapeutics (APRE) Competitors $1.50 -0.04 (-2.39%) Closing price 04/17/2025 03:49 PM EasternExtended Trading$1.48 -0.02 (-1.03%) As of 04/17/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APRE vs. XLO, ELYM, KPTI, DTIL, ATRA, SPRO, CNTB, CELU, FBLG, and INKTShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Xilio Therapeutics (XLO), Eliem Therapeutics (ELYM), Karyopharm Therapeutics (KPTI), Precision BioSciences (DTIL), Atara Biotherapeutics (ATRA), Spero Therapeutics (SPRO), Connect Biopharma (CNTB), Celularity (CELU), FibroBiologics (FBLG), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Xilio Therapeutics Eliem Therapeutics Karyopharm Therapeutics Precision BioSciences Atara Biotherapeutics Spero Therapeutics Connect Biopharma Celularity FibroBiologics MiNK Therapeutics Aprea Therapeutics (NASDAQ:APRE) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Do analysts prefer APRE or XLO? Aprea Therapeutics currently has a consensus price target of $15.50, suggesting a potential upside of 933.06%. Xilio Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 432.20%. Given Aprea Therapeutics' higher possible upside, research analysts plainly believe Aprea Therapeutics is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is APRE or XLO more profitable? Xilio Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,029.50%. Aprea Therapeutics' return on equity of -57.86% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aprea Therapeutics-1,029.50% -57.86% -47.94% Xilio Therapeutics N/A -211.50%-80.31% Does the MarketBeat Community favor APRE or XLO? Aprea Therapeutics received 44 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 57.14% of users gave Aprea Therapeutics an outperform vote. CompanyUnderperformOutperformAprea TherapeuticsOutperform Votes5657.14% Underperform Votes4242.86% Xilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Which has preferable earnings and valuation, APRE or XLO? Aprea Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAprea Therapeutics$580K14.21-$14.29M-$2.38-0.63Xilio Therapeutics$6.34M6.13-$76.40M-$1.28-0.59 Which has more volatility & risk, APRE or XLO? Aprea Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Does the media favor APRE or XLO? In the previous week, Aprea Therapeutics' average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score. Company Overall Sentiment Aprea Therapeutics Neutral Xilio Therapeutics Neutral Do insiders & institutionals believe in APRE or XLO? 34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 12.8% of Aprea Therapeutics shares are held by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAprea Therapeutics beats Xilio Therapeutics on 9 of the 15 factors compared between the two stocks. Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.24M$6.46B$5.32B$7.35BDividend YieldN/A3.21%5.47%4.34%P/E Ratio-0.536.9521.9417.82Price / Sales14.21231.01380.9597.73Price / CashN/A65.6738.3134.64Price / Book0.335.936.453.98Net Income-$14.29M$143.22M$3.22B$247.81M7 Day Performance-3.20%4.28%5.85%3.19%1 Month Performance-38.00%-13.11%-9.58%-7.70%1 Year Performance-71.96%-8.51%11.85%1.49% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics2.5377 of 5 stars$1.50-2.4%$15.50+933.1%-72.3%$8.24M$580,000.00-0.537XLOXilio Therapeutics2.0939 of 5 stars$0.67-1.0%$4.00+494.4%-34.6%$34.84M$6.34M-0.3970Gap DownELYMEliem TherapeuticsN/A$1.17+1.7%N/A-67.3%$34.81MN/A-2.219KPTIKaryopharm Therapeutics3.1283 of 5 stars$4.04+4.7%$57.50+1,323.3%-71.8%$34.01M$145.24M-3.96380Short Interest ↑Negative NewsHigh Trading VolumeDTILPrecision BioSciences3.5262 of 5 stars$4.40-4.6%$37.67+756.1%-48.5%$33.75M$68.70M73.35200Short Interest ↑ATRAAtara Biotherapeutics3.9548 of 5 stars$5.73+2.5%$17.75+209.8%-62.7%$33.57M$128.94M-0.22330News CoverageSPROSpero Therapeutics4.1022 of 5 stars$0.60+3.1%$5.00+733.6%-46.1%$33.53M$27.40M8.57150CNTBConnect Biopharma3.4957 of 5 stars$0.60-4.7%$8.00+1,233.1%-52.0%$33.22M$24.12M0.00110Short Interest ↓Gap DownHigh Trading VolumeCELUCelularity0.2283 of 5 stars$1.39+0.7%N/A-48.7%$33.09M$48.20M0.00220Gap UpFBLGFibroBiologics1.5392 of 5 stars$0.87-0.7%$13.00+1,394.4%-88.3%$32.83MN/A-2.5610INKTMiNK Therapeutics3.087 of 5 stars$8.24-2.0%$37.50+355.1%-12.9%$32.68MN/A-2.1130Short Interest ↓Positive NewsGap Down Related Companies and Tools Related Companies XLO Competitors ELYM Competitors KPTI Competitors DTIL Competitors ATRA Competitors SPRO Competitors CNTB Competitors CELU Competitors FBLG Competitors INKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRE) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
